Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 1.00 |
| ▸ | TNKS | O95271 | 1/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 1/20 | 1.00 |
| ▸ | PARP14 | Q460N5 | 1/20 | 1.00 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 1.00 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 1.00 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29696002 | 1.00 | PARP1 (1.00) | PARP1ROCK2TNKSROCK1PARP14 | |
| SCHEMBL10260277 | 0.85 | ROCK2 (0.73) | PARP1ROCK2TNKSROCK1PARP14 | |
| SCHEMBL869572 | 0.79 | PARP1 (1.00) | PARP1ROCK2TNKSROCK1PARP14 | |
| SCHEMBL6224144 | 0.78 | ALDH1A1 (0.73) | PARP1ROCK2TNKSROCK1PARP14 | |
| SCHEMBL3371602 | 0.77 | PARP1 (0.63) | PARP1ROCK2TNKSROCK1PARP14 | |
| SCHEMBL9787048 | 0.75 | L3MBTL1 (0.73) | PARP1ROCK2TNKSROCK1PARP14 | |
| SCHEMBL14297567 | 0.74 | ROCK2 (0.59) | PARP1ROCK2TNKSROCK1PARP14 | |
| SCHEMBL9644385 | 0.73 | TDP1 (0.65) | PARP1ROCK2TNKSROCK1PARP14 | |
| SCHEMBL11646427 | 0.73 | ROCK2 (0.57) | PARP1ROCK2TNKSROCK1PARP14 | |
| SCHEMBL11646129 | 0.73 | ROCK2 (0.57) | PARP1ROCK2TNKSROCK1PARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106998-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR AND RELATED COMPOSITION AND METHOD OF USE | PURDUE RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4739310-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | claimed |
| WO-2025007955-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2025-01-09 | — | — | WO | claimed |
| WO-2024217502-A1 | METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITOR COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-10-24 | — | — | WO | claimed |
| CN-113786409-B | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | 甫康（上海）健康科技有限责任公司 | 2024-04-02 | — | — | CN | claimed |
| US-20230123585-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CANCER USING DEUBIQUITINASE INHIBITORS | UNIV CHICAGO (US) | 2023-04-20 | — | — | US | claimed |
| EP-3337477-B1 | COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT | CONVALIFE SHANGHAI CO LTD (CN) | 2023-02-01 | — | — | EP | claimed |
| US-11291669-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | KARUS THERAPEUTICS LIMITED (GB) | 2022-04-05 | — | — | US | claimed |
| US-11229654-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | SENHWA BIOSCIENCES, INC. (TW) | 2022-01-25 | — | — | US | claimed |
| US-11191770-B2 | — | — | 2021-12-07 | — | — | US | claimed |
| CN-112334133-A | Quinolone analogs and salts thereof, compositions, and methods of use thereof | 生华生物科技股份有限公司 | 2021-02-05 | — | — | CN | claimed |
| WO-2019168688-A9 | QUINOLONE ANALOGS AND THEIR SALTS, COMPOSITIONS, AND METHOD FOR THEIR USE | SENHWA BIOSCIENCES, INC. (TW) | 2019-11-14 | — | — | WO | claimed |
| US-20190224209-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES, INC. (TW) | 2019-07-25 | — | — | US | claimed |
| WO-2026106998-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR AND RELATED COMPOSITION AND METHOD OF USE | PURDUE RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4739310-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | disclosed |
| WO-2017105382-A1 | CRYSTALLINE FORMS OF QUINOLONE ANALOGS AND THEIR SALTS | RYCKMAN DAVID M (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170166590-A1 | CRYSTALLINE FORMS OF QUINOLONE ANALOGS AND THEIR SALTS | SENHWA BIOSCIENCES, INC. (TW) | 2017-06-15 | — | — | US | disclosed |
| US-20170143737-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES, INC. (TW) | 2017-05-25 | — | — | US | disclosed |
| US-20170056336-A1 | CO-TARGETING ANDROGEN RECEPTOR SPLICE VARIANTS AND MTOR SIGNALING PATHWAY FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11191770-B2 | — | CXCR4, TLR7, CCR7 | PARP1 2554/4885ROCK2 1656/4885TNKS 2798/4885 |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | PARP1 2339/4885ROCK2 822/4885TNKS 2964/4885 |
| US-20170143737-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | CXCR4, CXCR6, TLR7 | PARP1 1475/4885ROCK2 2312/4885TNKS 960/4885 |
| US-20190224209-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | CXCR4, CXCR6, TLR7 | PARP1 1475/4885ROCK2 2312/4885TNKS 960/4885 |
| US-11291669-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | MCL1, MYC, XIAP | PARP1 33/4885ROCK2 1205/4885TNKS 204/4885 |
| US-11229654-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | CXCR4, CXCR6, TLR7 | PARP1 1475/4885ROCK2 2312/4885TNKS 960/4885 |
| US-20170166590-A1 | CRYSTALLINE FORMS OF QUINOLONE ANALOGS AND THEIR SALTS | UACA, SIRT5, TOP1 | PARP1 858/4885ROCK2 1796/4885TNKS 1778/4885 |
| US-20170056336-A1 | CO-TARGETING ANDROGEN RECEPTOR SPLICE VARIANTS AND MTOR SIGNALING PATHWAY FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | AR, MTOR, RICTOR | PARP1 2600/4885ROCK2 2300/4885TNKS 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.